Armata Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Armata Pharmaceuticals generated cash of -$47,423,000, which is less than the previous year. Cash used in financing activities reached the amount of $53,988,000 last year. Net change in cash is therefore -$1,569,000.
Cash Flow
| 2014 | -12.57M | -1.20M | 0 |
|---|---|---|---|
| 2015 | -9.78M | -210K | 12.78M |
| 2016 | -10.58M | -279K | 7.20M |
| 2017 | -9.19M | -58K | 8.67M |
| 2018 | -9.38M | -44K | 0 |
| 2019 | -15.58M | 2.87M | 8.97M |
| 2020 | -18.27M | -824K | 23.21M |
| 2021 | -23.57M | -1.30M | 25.51M |
| 2022 | -32.48M | -2.21M | 44.01M |
| 2023 | -47.42M | -8.13M | 53.98M |
ARMP Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 20.81M | 11.48M | 10.84M | 6.73M | 10.46M | 5.13M | 5.71M | 9.37M | 6.58M | 20.35M |
Operating activities | ||||||||||
Net income | -69.04M | -36.91M | -23.15M | -22.18M | -19.47M | -12.11M | -12.83M | -18.83M | -516K | 23.10M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 972K | 892K | 1.16M | 1.11M | 1.35M | 389K | 374K | 369K | 330K | 158K |
Stock-based compensation expense | 938K | 3.10M | 2.88M | 3.47M | 4.27M | 0 | 700K | 1.99M | 483K | 1.93M |
| Deferred income tax benefit | 938K | 3.10M | 2.88M | 3.47M | 4.27M | 0 | 700K | 1.99M | 483K | 1.93M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 1.05M | -2.42M | -467K | 0 | 0 | 381K | 100K | -25K | -92K |
Inventories | 0 | -1.05M | 2.42M | 467K | 0 | 0 | 0 | 105K | 0 | 0 |
Accounts payable | 39K | 3.66M | 184K | 544K | -1.37M | 343K | -838K | 298K | 296K | -977K |
Cash generated by operating activities | -47.42M | -32.48M | -23.57M | -18.27M | -15.58M | -9.38M | -9.19M | -10.58M | -9.78M | -12.57M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | -3.39M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -8.14M | -2.21M | -1.30M | -824K | -131K | -44K | -58K | -279K | -210K | -1.20M |
Acquisitions Net | 0 | 0 | 0 | 0 | 3.00M | 65K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -8.13M | -2.21M | -1.30M | -824K | 2.87M | -44K | -58K | -279K | -210K | -1.20M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 44.39M | 26.31M | 22.89M | 9.97M | 0 | 9.35M | 7.56M | 12.38M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -80K | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -173K | 0 | 0 |
Repayments of term debt | 54.02M | 0 | 0 | -717K | 0 | 0 | -815K | -117K | 0 | 0 |
Cash used in financing activities | 53.98M | 44.01M | 25.51M | 23.21M | 8.97M | 0 | 8.67M | 7.20M | 12.78M | 0 |
Net Change In Cash | -1.56M | 9.32M | 639K | 4.11M | -3.73M | 3.02M | -579K | -3.65M | 2.78M | -13.77M |
Cash at end of period | 19.24M | 20.81M | 11.48M | 10.84M | 6.73M | 8.15M | 5.13M | 5.71M | 9.37M | 6.58M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |